Second quarter financial results for biotechnology companies are coming in thick and fast and overall, for the larger biotech companies at least, their report cards have been positive. However, a few companies failed to live up to expectations. Read More
DUBLIN – Sanofi SA has stepped in where Johnson & Johnson stepped out, signing up to a diabetes alliance with Evotec AG focused on beta cell regeneration, in return for €3 million (US$3.3 million) up front and more than €300 million in milestone payments. Read More
Aquinox Pharmaceuticals Inc. CEO David Main called bladder pain syndrome/interstitial cystitis (BPS/IC) "a sizable opportunity that few appreciate," but Wall Street's reaction to phase II secondary endpoint data with AQX-1125 suggested investors were climbing aboard in hordes, as the firm (NASDAQ:AQXP) closed trading Friday at $10.42, up $8.63, or 482 percent. Read More
There is "a mysterious relationship between antioxidants and boosting the immune system," Howard Petrie told BioWorld Today. Antioxidants clearly boost immune function. But the molecular mechanisms of how they do so remain largely unclear. Read More
NEW DELHI – India deferred its talks with the European Union on a broad-based investment trade agreement "for the present, in response to the European Commission's [EC's] July ban on 700 Indian generics." Trade talks between the EU and India were to resume in August, after a gap of two years. Read More
LSK Biopharma inked an exclusive license agreement with the University of Utah's Huntsman Cancer Institute (HCI) to develop and commercialize HCI-1401, an orally bioavailable, small-molecule, irreversible inhibitor of Bruton's tyrosine kinase (BTK). Read More
As part of its second quarter earnings report, Biocryst Pharmaceuticals Inc. said it was adding a 14-day treatment cohort to its phase I study in healthy volunteers of kallikrein inhibitor BCX7353, intended as a next-generation, once-daily hereditary angioedema (HAE) therapy. Read More
CTI Biopharma Corp., of Seattle, reported second quarter review of $1.1 million, with net product revenues of $800,000 from non-Hodgkin's lymphoma drug Pixuvri (pixantrone). Read More
Collegium Pharmaceutical Inc., of Canton, Mass., reported that a Sept. 11 joint meeting of the FDA's Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee has been scheduled to review the new drug application for lead candidate Xtampza ER (oxycodone extended-release capsules). Read More
ALK-Abellos A/S, of Copenhagen, Denmark, said its partner for Japan, Torii Pharmaceutical Co. Ltd., of Tokyo, reported positive results from its phase II/III trial of sublingual allergy immunotherapy tablet (SLIT-tablet) for Japanese cedar tree pollen allergic rhinitis (hay fever). Read More
In the ring vaccination trial of Merck and Co. Inc.'s and Newlink Genetics Corp.'s VSV-EBOV vaccine, immediate administration has been 100 percent effective to date at preventing Ebola virus infections. Read More
